Excretion of digoxin and its metabolites in urine after a single oral dose in healthy subjects
β Scribed by J. O. Magnusson; B. Bergdahl; C. Bogentoft; U. E. Jonsson; L. Tekenbergs
- Publisher
- John Wiley and Sons
- Year
- 1982
- Tongue
- English
- Weight
- 379 KB
- Volume
- 3
- Category
- Article
- ISSN
- 0142-2782
No coin nor oath required. For personal study only.
β¦ Synopsis
Abstract
The 3βday urinary excretion of digoxin, its conjugated and unconjugated hydrolytic metabolites and dihydrodigoxin, was studied in 8 healthy men after oral administration of tritiated digoxin. Analysis was performed by high pressure liquid chromatography (HPLC). The total radioactivity corresponded to 45.4Β±2.0 per cent (mean Β± S.E.M.) of the dose. By HPLC 424 Β± 2.7 per cent was recovered before and 44.0 Β± 2.7 per cent after deconjugation of the samples. Digoxin and dihydrodigoxin constituted 40.3 Β± 2.9 per cent; of this 0.7 Β± 0.4 per cent was dihydrodigoxin. The sum of the hydrolytic metabolites was 2.1 Β± 0.3 per cent before and 3.4Β± 0.5 per cent after deconjugation. No correlation was found between gastric pH and the production of hydrolytic metabolites. The relative amount of these metabolites was maximal (mean 13.4 per cent of the excretion) in the 4.8 h sampling period. During the first 8 h an average of 8.6 per cent of the radioactivity was not recovered by HPLC. The metabolism of digoxin as judged by urinary excretion was limited and showed great variation during the early hours after treatment. The excretion of unchanged digoxin in some individuals constituted as little as 60 per cent over the first 12 h after dosing.
π SIMILAR VOLUMES
The pharmacokinetics of fluvoxamine after single oral administration of 25, 50, and 100mg fluvoxamine maleate was studied in a three-way cross-over study in 12 healthy male subjects. Fluvoxamine was administered orally in a solution. For doseproportionality, AUC, and C,-dose relationships were evalu
The single-and multiple-dose pharmacokinetics and dose-proportionality of oral dolasetron and its active metabolites over the therapeutic dose range was investigated in 18 healthy men. In an open-label, randomized, complete three-way crossover design, each subject received three separate doses: 50,
The pharmacokinetics of oral midazolam (Dormicum@, 15 mg) and loprazolam (Dormonoct@, 1 mg) were studied in eight healthy young volunteers in a cross-over design. Plasma concentrations of midazolam were measured with a gas chromatographic method and loprazolam concentrations were determined by a rad